Tim Street

100% Insulin Independence: Why Eledon’s Breakthrough is a Pillar, Not a Cure

Eledon Pharmaceuticals recently achieved 100% insulin independence in an early-phase islet transplant trial using its anti-CD40L drug, tegoprubart. It’s a massive step forward in transplant immunology that avoids the toxicity of standard drugs. But why isn't it a cure yet, and how does it fit into the actual blueprint of a functional cure?

https://www.diabettech.com/100-insulin-independence-why-eledons-breakthrough-is-a-pillar-not-a-cure/?utm_source=mastodon&utm_medium=jetpack_social

100% Insulin Independence: Why Eledon’s Breakthrough is a Pillar, Not a Cure
Eledon Pharmaceuticals recently achieved 100% insulin independence in an early-phase islet transplant trial using its anti-CD40L drug, tegoprubart. It’s a massive step forward in transplant immunology that avoids the toxicity of standard drugs. But why isn't
https://www.diabettech.com/100-insulin-independence-why-eledons-breakthrough-is-a-pillar-not-a-cure/
#cure #Diabetes #cure #Diabetes #Eledon #tegoprubart

Explore a Decade of Diabetes Insights with Diabettech AI After 10+ years of documenting the diabetes landscape, Diabettech is launching diabettech.ai—a custom research tool designed to help you navigate a decade’s worth of articles and reports. Powered by an LLM interface, this tool allows you to "interrogate" the site’s data to find specific answers on everything from cures to n=1 observations. ​Key highlights of the beta launch: ​Targeted Accuracy: Built to stick strictly to Diabettech articles and comments to minimize "hallucinations." ​Research-Focused: Optimized as a precision tool rather than a standard chatbot to provide relevant article links. ​Sustainable Design: Privately funded and optimized for efficiency to manage resource costs and query speeds. ​Ready to dive into the archives? Visit diabettech.ai to start your research and share your feedback on the beta experience. https://www.diabettech.com/introducing-diabettech-ai/?utm_source=mastodon&utm_medium=jetpack_social

Explore a Decade of Diabetes Insights with Diabettech AI After 10+ years of documenting the diabetes landscape, Diabettech is launching diabettech.ai—a custom research tool designed to help you navigate a decade’s worth of articles and reports. Powered by an LLM interface, this tool allows you to "interrogate" the site’s data to find specific answers on everything from cur https://www.diabettech.com/introducing-diabettech-ai/ #AI #Diabetes #AI #beta #Diabetes #diabettechai #LLM #Research

Diabettech AI Welcome to Diabettech AI. Please enjoy the opportunity to delve into more thna ten years of content from Diabettech.com via our LLM interface. Diabettech AI is for informational purposes. Consult your clinic for medical advice. https://www.diabettech.com/ai/

The Daily Bolus: Red Cell Sponges, Microbiome Signatures, and Cyborg Cells Today’s research is moving beyond the traditional "big three" of glucose disposal—liver, muscle, and fat. We explore how red blood cells can be recruited as metabolic "sponges," how AI-driven gut signatures are catching insulin resistance earlier than ever, and why an electronic "cyborg" mesh might be the key to making lab-grown pancreatic cells finally function like the real thing. It’s a steady shift toward an integrated, multi-system approach to metabolic health. https://www.diabettech.com/the-daily-bolus-red-cell-sponges-microbiome-signatures-and-cyborg-cells/?utm_source=mastodon&utm_medium=jetpack_social

Now We Know What a Type 1 Cure Could Look Like

The Type 1 cure is no longer theoretical. Human data now points to a blueprint: working cells, immune evasion, and durable immune modulation.

https://www.diabettech.com/now-we-know-what-a-type-1-cure-could-look-like/?utm_source=mastodon&utm_medium=jetpack_social

Notices

https://www.diabettech.com/notices/

The Daily Bolus: Early Warnings, Genetic Cloaks, and the Seven-Year Shield Whilst the title of this edition sounds like something out of  science fiction, in it we see a masterclass in "biological intelligence." As of February 5, 2026, the signal cutting through the noise has shifted from hardware on the skin to the deep cellular architecture of the body. From "immune niches" that act as early-warning systems to cell therapies that refuse to quit after seven years, the… https://www.diabettech.com/the-daily-bolus-early-warnings-genetic-cloaks-and-the-seven-year-shield/

The Daily Bolus: Early Warnings, Genetic Cloaks, and the Seven-Year Shield Whilst the title of this edition sounds like something out of  science fiction, in it we see a masterclass in "biological intelligence." As of February 5, 2026, the signal cutting through the noise has shifted from hardware on the skin to the deep cellular architecture of the body. From "immune niches" https://www.diabettech.com/the-daily-bolus-early-warnings-genetic-cloaks-and-the-seven-year-shield/ #DailyBolus

The Daily Bolus: Mechanism over metrics, biology over dashboards The developments highlighted in the bolus today reinforce a theme Diabettech has been circling for years: the most meaningful progress in diabetes does not come from squeezing ever more signal out of glucose curves, but from understanding the biology that sits underneath them. Not all of these are from the past 24 hours, but all present an interesting, and in some cases, different take on what might be… https://www.diabettech.com/the-daily-bolus-mechanism-over-metrics-biology-over-dashboards/

The Daily Bolus: Mechanism over metrics, biology over dashboards The developments highlighted in the bolus today reinforce a theme Diabettech has been circling for years: the most meaningful progress in diabetes does not come from squeezing ever more signal out of glucose curves, but from understanding the biology that sits underneath them. Not all of these are from the past 24 hours, https://www.diabettech.com/the-daily-bolus-mechanism-over-metrics-biology-over-dashboards/ #DailyBolus

The Daily Bolus: Et tu, B Cells?

Recent news has been defined by a pivot toward "biological intelligence." As of January 21, 2026, the signal cutting through the noise isn't just about managing the disease after it arrives, but about uncovering the "hidden" sabotage within our immune systems and identifying at-risk children before the first symptom ever appears. 1. The "Sinister" Saboteurs: B Cells vs. The Peacekeepers…

https://www.diabettech.com/the-daily-bolus-et-tu-b-cells/

The Daily Bolus: Et tu, B Cells?
Recent news has been defined by a pivot toward "biological intelligence." As of January 21, 2026, the signal cutting through the noise isn't just about managing the disease after it arrives, but about uncovering the "hidden" sabotage within our immune systems and identifying at-risk children before the first symptom ever appears.
1. The "Sinister" Saboteurs: B Cells vs. The Peacekeepe
https://www.diabettech.com/the-daily-bolus-et-tu-b-cells/
#DailyBolus

What If Type 1 Diabetes Was Treatable — If You Found It Early Enough?

For most of its history, type 1 diabetes (T1D) has been diagnosed late. By the time symptoms appear, the autoimmune destruction of pancreatic beta cells has usually been underway for years, with a substantial proportion of insulin-producing capacity already lost. The consequences of this late diagnosis are familiar: diabetic ketoacidosis (DKA), emergency hospital admissions, and an abrupt, often…

https://www.diabettech.com/what-if-type-1-diabetes-was-treatable-if-you-found-it-early-enough/

What If Type 1 Diabetes Was Treatable — If You Found It Early Enough?
For most of its history, type 1 diabetes (T1D) has been diagnosed late. By the time symptoms appear, the autoimmune destruction of pancreatic beta cells has usually been underway for years, with a substantial proportion o
https://www.diabettech.com/what-if-type-1-diabetes-was-treatable-if-you-found-it-early-enough/
#Diabetes #BetaCellProtectionTherapies #Diabetes #FutureStates #GPPAD #NextCell #T1DScout #T1DScreening

The Daily Bolus: What happened over the weekend?

The Daily Bolus The weekend news has produced a rare mix of genuinely interesting diabetes science alongside the usual commercial background noise. Notably, some of the most consequential developments did not originate from device manufacturers or glucose-lowering drug pipelines, but from immune biology, metabolomics, and long-term disease-modification research. Disease Modification: Immune and Cellular Approaches…

https://www.diabettech.com/the-daily-bolus-what-happened-over-the-weekend/

The Daily Bolus: What happened over the weekend?
The Daily Bolus
The weekend news has produced a rare mix of genuinely interesting diabetes science alongside the usual commercial background noise. Notably, some of the most consequential developments did not originate from device manufacturers or glucose-lowering drug pipelines, but from immune biology, metabolomics, and long-term disease-modification
https://www.diabettech.com/the-daily-bolus-what-happened-over-the-weekend/
#DailyBolus

The Daily Bolus: Enhancing Biological Precision?

The last 24 hours in the diabetes space have been characterized by a quiet but firm shift from "what if" to "how soon." As of January 15, 2026, the signal cutting through the noise isn't a singular "cure" headline, but a series of technical milestones in automated delivery, genomic risk-mapping, and the ongoing, messy evolution of implanted cell therapies. 1. Genetic Fingerprinting for Type 2 Risk…

https://www.diabettech.com/the-daily-bolus-enhancing-biological-precision/

The Daily Bolus: Enhancing Biological Precision?
The last 24 hours in the diabetes space have been characterized by a quiet but firm shift from "what if" to "how soon." As of January 15, 2026, the signal cutting through the noise isn't a singular "cure" headline, but a series of technical milestones in automated delivery, genomic risk-mapping, and the ongoing, messy evolution of implanted cell therapi
https://www.diabettech.com/the-daily-bolus-enhancing-biological-precision/
#DailyBolus